Keylika
YC S22San Francisco, US · Founded 2022 · 1 employees · 1 known investors
Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.
BiotechHealthtechMedical DevicesAI-powered Drug DiscoveryDrug DeliveryNanotechnologyTherapeuticsin /keylika/@keylika_incycombinator.com ↗
Founders & leadership· Y Combinator alumni (S22)
BC
Buddha Chaudhuriin𝕏Founder
FC
Frederik CeyssensinFounder
BP
Buddhadev P. Chaudhuri, PhDinCEO & Co-Founder
FC
Frederik Ceyssens, PhDCTO & Co-Founder
Investors · 1
In the news
- Keylika Develops World's First Buccal Patch for Iron Deficiency Anemia (IDA) | Entrepreneurentrepreneur.com · 2025
- Keylika develops first Buccal Patch for Iron Deficiency Anemia (IDA) - Arabian Business: Latest News on the Middle East, Real Estate, Finance, and Morearabianbusiness.com · 2025
- Bootstrapped Indian Startup Innovating Treatment for Eczema, Itch & Beyond | Entrepreneurentrepreneur.com · 2025
- TACKLING IRON-DEFICIENCY ANAEMIA: A LEAP FORWARD WITH A REVOLUTIONARY BUCCAL PATCH - ONdrugDeliveryondrugdelivery.com · 2024
- Bootstrapping in Biotech: How Keylika’s Founding Story Highlights Key Entrepreneurship Lessonsusatoday.com · 2024
- Keylika: Redefining the Standard of Care for Iron Deficiencyycombinator.com · 2022